LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article: Dois regimes monetários

    Noronha, Luis Eduardo Pitta de

    Oikos : revista de economia heterodoxa Bd. V.2006=Nr. 6, S. 66-86

    uma análise comparativa do período pós plano real

    2006  

    Author's details Luis Eduardo Pitta de Noronha
    Language Portuguese
    Size graph. Darst.
    Publishing place Rio de Janeiro
    Document type Article
    ZDB-ID 2113724-9
    Database ECONomics Information System

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  2. Article ; Online: CANadian CAnagliflozin REgistry: Patient-Reported Outcomes of Canagliflozin in the Treatment of Type 2 Diabetes Mellitus in Canadian Clinical Practice.

    Woo, Vincent / Bell, Alan / Clement, Maureen / Noronha, Luis / Tsoukas, Michael A / Camacho, Fernando / Traina, Shana / Georgijev, Natasha / Rose, Jennifer B / Sorabji, Delna / Bajaj, Harpreet S

    Canadian journal of diabetes

    2019  Volume 43, Issue 7, Page(s) 464–471

    Abstract: Objectives: To describe patient-reported outcomes (PROs) after initiation of treatment with canagliflozin (CANA) for type 2 diabetes mellitus (T2DM) in a real-world Canadian setting.: Methods: CANadian CAnagliflozin REgistry (CanCARE) is a ... ...

    Abstract Objectives: To describe patient-reported outcomes (PROs) after initiation of treatment with canagliflozin (CANA) for type 2 diabetes mellitus (T2DM) in a real-world Canadian setting.
    Methods: CANadian CAnagliflozin REgistry (CanCARE) is a prospective, observational, single-arm, real-world Canadian study of the effectiveness and safety of CANA for the treatment of T2DM in 527 subjects. PRO measures were collected in CanCARE using the Current Health Satisfaction Questionnaire (CHES-Q) at baseline and after 3, 6 and 12 months of CANA treatment to examine patient satisfaction regarding weight and overall health. Associations between changes in satisfaction with weight, systolic blood pressure (SBP) and glycated hemoglobin (A1C) levels were also investigated.
    Results: Proportion of patients satisfied with their body weight and overall health increased from 22.1% and 26.9% at baseline to 32.4% and 49.2% after 12 months of CANA treatment, respectively. Satisfaction rates also increased on CHES-Q domains representing physical and emotional health. Correlations were found between improvement in satisfaction with body weight and weight loss (r=-0.29; p<0.01) and between improvements in satisfaction with overall health and weight loss (r=-0.13; p=0.03) and SBP (r=-0.17; p<0.01), but not with changes in A1C level.
    Conclusions: Treatment with CANA is associated with improvements in satisfaction with body weight and overall health, which may be important drivers of patient self-management and hold the potential to positively influence long-term outcomes in T2DM.
    MeSH term(s) Blood Glucose/analysis ; Body Weight ; Canada ; Canagliflozin/therapeutic use ; Diabetes Mellitus, Type 2/drug therapy ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Patient Reported Outcome Measures ; Practice Patterns, Physicians'/statistics & numerical data ; Prognosis ; Prospective Studies ; Registries/statistics & numerical data ; Sodium-Glucose Transporter 2 Inhibitors/therapeutic use ; Surveys and Questionnaires ; Weight Loss
    Chemical Substances Blood Glucose ; Sodium-Glucose Transporter 2 Inhibitors ; Canagliflozin (0SAC974Z85)
    Language English
    Publishing date 2019-04-16
    Publishing country Canada
    Document type Journal Article ; Observational Study
    ISSN 2352-3840
    ISSN (online) 2352-3840
    DOI 10.1016/j.jcjd.2019.04.004
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  3. Article ; Online: CANadian CAnagliflozin REgistry: Effectiveness and safety of canagliflozin in the treatment of type 2 diabetes mellitus in Canadian clinical practice.

    Woo, Vincent / Bell, Alan / Clement, Maureen / Noronha, Luis / Tsoukas, Michael A / Camacho, Fernando / Traina, Shana / Georgijev, Natasha / Culham, Matthew D / Rose, Jennifer B / Rapattoni, Wally / Bajaj, Harpreet S

    Diabetes, obesity & metabolism

    2018  Volume 21, Issue 3, Page(s) 691–699

    Abstract: Aim: There is limited information concerning the effects of canagliflozin (CANA), a sodium-glucose co-transporter 2 inhibitor (SGLT2i) in a real-world clinical setting in Canada. CanCARE is a 12-month, prospective, observational analysis to demonstrate ... ...

    Abstract Aim: There is limited information concerning the effects of canagliflozin (CANA), a sodium-glucose co-transporter 2 inhibitor (SGLT2i) in a real-world clinical setting in Canada. CanCARE is a 12-month, prospective, observational analysis to demonstrate the effectiveness and safety of CANA in usual clinical practice in Canada.
    Materials and methods: SGLT2i-naïve adult patients with type 2 diabetes mellitus (T2DM) (n = 527) on a stable antihyperglycemic agent (AHA) regimen with glycated hemoglobin (A1C) ≥ 7%, an estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73m
    Results: Significant improvement from baseline in mean HbA1c levels were observed at 6 months (-0.90%; 95% CI, -1.02, -0.78) and at 12 months (-1.04%; 95% CI, -1.15, -0.92), regardless of duration of diabetes or background AHA treatment regimen. Similarly, significant decreases in systolic blood pressure (-4.65 mm Hg); body weight (-3.24 kg), waist circumference (-2.91 cm) and body mass index (-1.15 kg/m
    Conclusion: CANA provided sustained clinically meaningful improvements in cardiometabolic parameters in this study in a real-world setting, confirming findings from randomized controlled trials.
    MeSH term(s) Adult ; Aged ; Canada ; Canagliflozin/adverse effects ; Canagliflozin/therapeutic use ; Diabetes Mellitus, Type 2/drug therapy ; Diabetes Mellitus, Type 2/epidemiology ; Drug-Related Side Effects and Adverse Reactions/epidemiology ; Electronic Health Records/statistics & numerical data ; Female ; General Practice/statistics & numerical data ; Humans ; Male ; Middle Aged ; Registries ; Treatment Outcome
    Chemical Substances Canagliflozin (0SAC974Z85)
    Language English
    Publishing date 2018-12-05
    Publishing country England
    Document type Journal Article ; Multicenter Study ; Observational Study ; Research Support, Non-U.S. Gov't
    ZDB-ID 1454944-x
    ISSN 1463-1326 ; 1462-8902
    ISSN (online) 1463-1326
    ISSN 1462-8902
    DOI 10.1111/dom.13573
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5442: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top